SR 0379

Drug Profile

SR 0379

Alternative Names: SR-0379

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Osaka University School of Medicine
  • Developer Shionogi
  • Class Peptide antibiotics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; MTOR protein modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Leg ulcer

Most Recent Events

  • 04 Sep 2017 Phase-II clinical trials in Leg ulcer (In adults) in Japan (Topical) (UMIN000028750)
  • 29 Oct 2015 Shionogi acquires SR 0379 from FunPep
  • 29 Oct 2015 Preclinical trials in Pressure ulcer in Japan (Topical) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top